AI Insight
This study compared the therapeutic effectiveness of human mesenchymal stromal cells (MSCs) from three different tissue sources—bone marrow, adipose tissue, and umbilical cord—in treating kidney ischemia reperfusion injury in mice. Using comprehensive tracking and assessment methods, researchers found that all three MSC types showed minimal beneficial effects on kidney function and tissue health, became trapped in the lungs without reaching the kidneys, and completely disappeared within seven days of administration.
Why it matters
These findings challenge the potential of MSCs as a viable therapy for acute kidney injury, suggesting that current delivery methods may be ineffective regardless of the tissue source used. The results raise important questions about translation of MSC therapies to clinical practice and indicate that alternative approaches or delivery methods may be needed.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Rodent models of kidney disease have been widely used to assess the efficacy, safety and mode of action of mesenchymal stromal cells (MSCs) as therapies. However, because kidney disease models, MSC type and the methods used to assess kidney injury tend to differ between research groups, it is difficult to obtain data that are sufficiently robust and reproducible to support clinical translation. We present here for the first time a side-by-side analysis of the performance of human MSCs derived from the most commonly used tissue sources, bone marrow (BM-), adipose- (A-) and umbilical cord (UC-), in a kidney ischaemia reperfusion injury (IRI) model in mice. For each animal, we performed a comprehensive assessment of kidney function and health by longitudinal transdermal measurements of sinistrin clearance, serum biomarker levels at the experimental endpoint, and histopathological scoring of sections from left and right kidneys. Furthermore, we tracked the MSCs by bioluminescence imaging in the injured mice to determine their viability over time and their capacity for homing to the damaged kidneys. Our results reveal that only modest if any beneficial effects of the MSC treatments were detectable on kidney function and histology, irrespective of cell type administered. Furthermore, all three MSC types were sequestered in the lungs without reaching the kidneys, and had completely disappeared within 7 days. Our data suggest that none of the MSC types has the capability to improve renal health following IRI to a meaningful extent, questioning their suitability as a clinical therapy.